VLA

Valneva Announces Closing of Upsized €102.9 Million Global Offering

Retrieved on: 
Tuesday, October 4, 2022
Electric Bond and Share Company v. Securities and Exchange Commission, AMF, Telephone, ADS, Vaccine, LLC, Jefferies Group, Madison Avenue, Euronext Paris, Attention, Nasdaq, Goldman Sachs, ADSS, Infection, American depositary receipt, Company, Form, Guggenheim Partners, Prospectus, Chikungunya, Note, Lyme disease, U.S. Securities and Exchange Commission, Private, VLA, Security (finance), Global

Aggregate gross proceeds of the Global Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately 102.9 million ($99.9 million).

Key Points: 
  • Aggregate gross proceeds of the Global Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately 102.9 million ($99.9 million).
  • Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as joint bookrunners for the Global Offering.
  • Copies of the Companys 2021 URD, as amended, is available free of charge on the Companys website.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares

Retrieved on: 
Friday, September 30, 2022
Nasdaq, ADS, Central bank, Note, Goldman Sachs, Commercial code, U.S. Securities and Exchange Commission, Research, Prospectus, Council, ISIN, Sale, Supervisory board, Company, European, Person, Code, ADSS, AMF, Attention, VLA, Vaccine, Chikungunya, Telephone, Marketing, Guggenheim Partners, Private, Lyme disease, European Parliament, LLC, Madison Avenue, Jefferies Group, European Central Bank, Financial Oversight and Management Board for Puerto Rico, Form, American depositary receipt, Infection, Compartment, Security (finance), Life insurance, Medical device, Global, EU, Euronext Paris, Euronext

The remaining ordinary shares sold in the Global Offering were primarily purchased by the Companys existing U.S. and European investors.

Key Points: 
  • The remaining ordinary shares sold in the Global Offering were primarily purchased by the Companys existing U.S. and European investors.
  • The gross proceeds of the sale of 21,000,000 ordinary shares (including in the form of ADSs) in the Global Offering are expected to be approximately $99.9 million (102.9 million).
  • The Company estimates that the net proceeds of the Global Offering will be approximately $93.1 million (96.0 million), after deducting approximately $6.0 million (6.2 million) in underwriting commissions and approximately $0.7 million (0.8 million) in offering expenses.
  • The Global Offering is subject to an underwriting agreement covering the entirety of the Global Offering.

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Retrieved on: 
Wednesday, September 28, 2022
Nasdaq, ADS, Note, Goldman Sachs, Commercial code, U.S. Securities and Exchange Commission, URD, Research, Prospectus, Council, Sale, Supervisory board, Company, European, Person, Code, ADSS, AMF, Attention, SEC, Conseil, Intention, VLA, Vaccine, Chikungunya, Telephone, Marketing, Guggenheim Partners, Private, Lyme disease, European Parliament, LLC, Madison Avenue, Jefferies Group, Form, American depositary receipt, Euronext Paris, Infection, Security (finance), Global, EU, Euronext

Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering.

Key Points: 
  • Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering will be offered by the Company.
  • The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the number of ADSs and ordinary shares sold in the Global Offering, will be determined following a book building process commencing immediately.
  • Bpifrance Participations S.A., which is an existing shareholder, has indicated an interest in purchasing up to an aggregate of 5.0 million of the ordinary shares in the Global Offering at the offering price.

Avionics Market worth $66.3 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, September 26, 2022
Aircraft, Knowledge, GEM, EFIS, RTA, Safety, BAE Systems, MAK Technologies, Inc., Control panel, Electronic flight instrument system, Air travel, UAV, Fighter aircraft, VLA, Application, L3Harris Technologies, Air data computer, Commercial aviation, Component, USD, Astronautics Corporation of America, General Electric Company, Intelligence, Region, WBA, Synthetic air data system, SME, General aviation, RWA, Raytheon Technologies, Research, Curtiss-Wright, Honeywell, NBA, Cockpit display system, CAGR, Airline, Weapon, Marketing, SS7 probe, Platform

CHICAGO, Sept. 26, 2022 /PRNewswire/ -- Avionics Market size is projected to grow from USD 46.7 Billion in 2022 to USD 66.3 Billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Sept. 26, 2022 /PRNewswire/ -- Avionics Market size is projected to grow from USD 46.7 Billion in 2022 to USD 66.3 Billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • Based on system, the navigation segment is projected to lead the market during the forecast period.
  • It is projected that demand for components like air data computers and altimeters would increase at the rapid pace.
  • Based on Fit, the line fit segment is projected to lead the avionics market during the forecast period.

Avionics Market worth $66.3 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, September 26, 2022
Aircraft, Knowledge, GEM, EFIS, RTA, Safety, BAE Systems, MAK Technologies, Inc., Control panel, Electronic flight instrument system, Air travel, UAV, Fighter aircraft, VLA, Application, L3Harris Technologies, Air data computer, Commercial aviation, Component, USD, Astronautics Corporation of America, General Electric Company, Intelligence, Region, WBA, Synthetic air data system, SME, General aviation, RWA, Raytheon Technologies, Research, Curtiss-Wright, Honeywell, NBA, Cockpit display system, CAGR, Airline, Weapon, Marketing, SS7 probe, Platform

CHICAGO, Sept. 26, 2022 /PRNewswire/ -- Avionics Market size is projected to grow from USD 46.7 Billion in 2022 to USD 66.3 Billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Sept. 26, 2022 /PRNewswire/ -- Avionics Market size is projected to grow from USD 46.7 Billion in 2022 to USD 66.3 Billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • Based on system, the navigation segment is projected to lead the market during the forecast period.
  • It is projected that demand for components like air data computers and altimeters would increase at the rapid pace.
  • Based on Fit, the line fit segment is projected to lead the avionics market during the forecast period.

Valneva Provides Further Update on its COVID-19 Activities

Retrieved on: 
Monday, September 26, 2022
Lyme disease, COVID-19, 1018, World, Severe acute respiratory syndrome coronavirus 2, World Health Organization, Vaccination, Company, VLA, Vero, EU, Technology, Vaccine, Nasdaq, Chikungunya, WHO, VLA2001, Marketing, CpG, Saint-Herblain, Euronext Paris, EMA, Infection, Pharmaceutical industry, Kingdom

Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities.

Key Points: 
  • Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities.
  • The Company is in active discussions with a prospective partner for potentially funding the development of a second-generation COVID-19 vaccine.
  • Valneva currently has agreements to supply VLA2001 to certain EU Member States2 and the Kingdom of Bahrain6.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

Retrieved on: 
Friday, September 16, 2022
Lyme disease, COVID-19, 1018, World, Severe acute respiratory syndrome coronavirus 2, World Health Organization, Vaccination, European Commission, Company, IDT Corporation, VLA, Vero, EU, History, Biosafety level, Technology, Vaccine, Nasdaq, IDT, Chikungunya, WHO, VLA2001, Marketing, CpG, Saint-Herblain, Euronext Paris, EMA, Infection, Kingdom

As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.

Key Points: 
  • As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
  • IDT Biologika is an innovative biotech company with a successful history dating back 100 years.
  • In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Retrieved on: 
Thursday, September 8, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Health care, Glioblastoma, Fatigue, EU, CEO, Cirrhosis, Pain, Research, Virus, Hepatocellular carcinoma, VLP, Company, Allergy, Chikungunya, EC, Patient, Vaccine, Cytomegalovirus, Hepatitis B, Headache, Liver disease, Liver cancer, Nasdaq, History, Anaphylaxis, Woman, Partnership, Myalgia, GBM, Hepatitis B virus, Disease, Tenderness, Lyme disease, Multimedia, Patent, Bavarian Nordic, MHRA, VBI, United Kingdom, CMV, European Commission, Immunodeficiency, Marketing, HBV, Achievement, VLA, Person, Infection, VAERS, Royal commission, Euronext Paris, Intention, Immune system, Clinical trial, Pregnancy, Pharmaceutical industry, Birth control, Valneva SE, European

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.

Key Points: 
  • Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
  • Thomas Lingelbach, President and CEO of Valneva, commented: We welcome this partnership with VBI which underlines Valnevas expertise in vaccine commercialization.
  • Jeff Baxter, President and CEO of VBI, commented: This partnership is a significant milestone for PreHevbri, enabling us to hit the ground running in Europe.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, EMA, Public health, EU, Technology, Safety, Vaccination, WHO, Vaccine, World, VLA, Infection, The Lancet, Lyme disease, Euronext Paris, Lancet, Journal, Severe acute respiratory syndrome coronavirus 2, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, 1018, Marketing, World Health Organization, Pharmaceutical industry, Kingdom, VLA2001, Valneva SE

Saint-Herblain (France), September 6, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that The Lancet Infectious Diseases (The Lancet ID), a peer-reviewed medical journal, has published the Companys pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.

Key Points: 
  • Saint-Herblain (France), September 6, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that The Lancet Infectious Diseases (The Lancet ID), a peer-reviewed medical journal, has published the Companys pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This Lancet publication is a strong scientific and developmental validation of the work that has been accomplished at Valneva.
  • The Company published safety and immunogenicity data from the Phase 1/2 trial of VLA2001 in the Journal of Infection3 in June 2022.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Retrieved on: 
Monday, August 29, 2022
AstraZeneca, COVID-19, EMA, BMI, EU, Technology, Safety, Vaccination, Immunity, WHO, Vaccine, VLA, Seroconversion, 3-fold, Infection, Hope, Lyme disease, Asthma, Euronext Paris, Severe acute respiratory syndrome coronavirus 2, MD, GMT, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, World, Marketing, RNA transfection, 1018, T cell, World Health Organization, Pharmaceutical industry, Kingdom, VLA2001

Saint-Herblain (France), August 29, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001.

Key Points: 
  • Saint-Herblain (France), August 29, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001.
  • Additional readouts from the Companys pivotal VLA2001-301 Cov-Compare trial showed persistent immunogenicity and first positive heterologous booster results following primary vaccination with ChAdOx1-S (AstraZeneca).
  • The safety profile of VLA2001 continues to be favorable and the vaccine was well tolerated up to Day 208.
  • This complements the positive homologous booster data weve generated in our Phase 1/2 and this Phase 3.